HCM in British Shorthairs
Hypertrophic cardiomyopathy is the most significant health concern in [British Shorthair](https://seniorpet.org/knowledge/breed/british-shorthair "Senior British Shorthair Health Guide") cats, with the breed having one of the highest predispositions among all cat breeds.
Key Statistics
| Fact | Details | |------|--------| | Prevalence | Estimated 10-15% of BSH population | | Inheritance | Autosomal dominant (variable penetrance) | | DNA test available | MYBPC3 mutation (partial detection) | | Screening method | Echocardiography (gold standard) | | Age of onset | Variable (2-15+ years) |Key Statistics & Research Data
Hypertrophic cardiomyopathy (HCM) is the most common cardiac disease in British Shorthair cats, with prevalence estimated at 8-15% of the breed population. The A31P MYBPC3 mutation is a significant risk factor specific to this breed (Source: Granström et al., JVIM, 2011; Kittleson et al., JVIM, 1999).
Echocardiographic screening detects preclinical HCM in 10-15% of apparently healthy British Shorthairs. Left ventricular wall thickness ≥6mm (end-diastole) is the primary diagnostic criterion in cats (Source: Fox et al., JVIM, 1995; Payne et al., JVIM, 2015).
Cats with HCM face a 3-5x increased risk of arterial thromboembolism (ATE), with 12-17% of HCM cats developing ATE during their lifetime. Clopidogrel (18.75 mg/cat/day) reduces ATE recurrence by 49% compared to aspirin (Source: Hogan et al., JVIM, 2015 — FAT CAT study).
Annual cardiac screening from age 1 is recommended for British Shorthairs. NT-proBNP testing has 85% sensitivity and 91% specificity for detecting moderate-to-severe HCM, serving as a useful pre-screening tool (Source: Fox et al., JVIM, 2011; Wess et al., JVIM, 2011).
What Is HCM?
- Thickening of the heart muscle (left ventricle)
- Reduces heart chamber size
- Impairs filling and relaxation
- Can lead to heart failure, blood clots, sudden death
- Progressive but rate varies
Screening Protocol
| Age | Frequency | Method | |-----|-----------|--------| | 1-3 years | Annual | Echocardiogram | | 3-7 years | Annual | Echocardiogram | | 7-12 years | Every 6-12 months | Echo + ProBNP | | 12+ years | Every 6 months | Echo + ProBNP + BP |
Clinical Signs
| Sign | Stage | |------|-------| | No signs (subclinical) | Early | | Increased respiratory rate at rest | Moderate | | Lethargy, reduced activity | Moderate | | Open-mouth breathing | Advanced (CHF) | | Sudden hind leg paralysis | Emergency (ATE) | | Sudden death | Can occur at any stage |
Treatment
| Medication | Purpose | When | |-----------|---------|------| | Atenolol | Slow heart rate | Moderate HCM | | Clopidogrel | Prevent blood clots | Moderate-Severe | | Furosemide | Remove fluid | Heart failure | | Benazepril/Telmisartan | Reduce workload | Moderate+ | | [Pimobendan](https://seniorpet.org/knowledge/pimobendan-vetmedin-heart-failure-guide "Pimobendan Heart Failure Guide") | Improve function | Selected cases |
Prognosis
| Stage | Median Survival | |-------|----------------| | Mild (subclinical) | Years to normal lifespan | | Moderate | 2-5 years with treatment | | Heart failure (CHF) | 3-18 months | | After blood clot (ATE) | 2-6 months (if survives) |
Key Takeaways
- HCM affects 10-15% of British Shorthairs — screening is essential, not optional
- Echocardiography is the gold standard (DNA test alone is insufficient)
- Many cats live years with mild HCM with no treatment needed
- Clopidogrel (anti-clot medication) is critical once moderate HCM is diagnosed
- Sudden hind leg paralysis (arterial thromboembolism) is a cardiac emergency
- Annual screening should start at age 1 and continue lifelong